Trial Profile
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors Ipsen
- 21 Oct 2013 New trial record